Drug Viability Assay
Drug Viability Assay - Related Videos
12:03
Viability Assays for Cells in Culture
0 Views •
Cited by 39 •
2014
Therapeutic compounds are often first examined in vitro with viability assays. Blind cell counts by a human observer can be highly sensitive to small changes in cell number but do not assess function. Computerized viability assays, as described here, can assess both structure and function in an objective manner.
03:20
XTT Assay: A Colorimetric Assay to Assess Cell Viability and Mitochondrial Activity
0 Views •
2023
This article describes the protocol for XTT assay which is a colorimetric assay to assess cell viability and mitochondrial activity.
05:47
Counting and Determining the Viability of Cultured Cells
0 Views •
Cited by 19 •
2008
Determining the number of cells in culture is important in standardization of culture conditions and in performing accurate quantitation experiments. In this video, we demonstrate how cells are counted using a hemacytometer.
03:40
β-Galactosidase Assay to Evaluate Drug-Induced Cytotoxicity in Parasites
0 Views •
2023
In this video, we describe a simple and robust method to determine the cytotoxic potential of a trypanocidal drug against a parasite, Trypanosoma cruzi, expressing the β-galactosidase enzyme. β-galactosidase serves as a cell lysis indicator, and its activity can be used to assess the effects of the drug.
04:05
Methyl Thiazolyl Tetrazolium or MTT Assay: A Colorimetric Assay to Measure Drug Resistance via Determination of Metabolic Activity in Cancer Cells
0 Views •
2023
This video describes the colorimetric assay, methyl thiazole tetrazolium (MTT) assay, to measure drug-induced cytotoxicity in cancer cells and determine their metabolic activity. This assay is based on the metabolic conversion of tetrazolium salts into colored products, reflecting the mitochondrial activity of cells.
FAQs
The measured signal determines which aspect of cell status is being used for comparison. Metabolic activity and ATP levels indicate cellular activity, whereas membrane integrity and dye conversion provide different viability-associated readouts. Selecting among these signals helps align the assay with the biological question and makes comparisons between treatments more interpretable.
Untreated controls provide the reference needed to judge how much a treatment changes the viability-associated signal. Comparing drug-exposed cancer cells with these controls allows researchers to identify reductions or preservation of survival-related measurements rather than interpreting raw signal values alone. This comparison supports evaluation across defined drug concentrations and treatment conditions.
Dose-dependent patterns show whether increasing drug concentration is associated with progressively stronger or weaker effects on cultured cancer cells. These results can help estimate inhibitory concentrations, which summarize the concentration associated with a specified reduction in the measured response. Researchers can then compare candidate therapies and select conditions for additional cancer biology studies.
A typical workflow begins by exposing cultured cancer cells to defined drug concentrations for a set period. Researchers then measure a selected viability-associated signal, such as metabolic activity, ATP levels, membrane integrity, or dye conversion, and compare the results with untreated controls. The resulting pattern supports evaluation of treatment effects across conditions.
Drug viability results can reveal whether cancer cells remain viable despite exposure to a treatment and whether that response changes across drug concentrations. Comparing response patterns among candidate therapies or experimental conditions helps researchers identify reduced drug sensitivity and investigate resistance-related behavior. These findings can guide the selection of treatments or conditions for further study.
Viability measurements are useful when researchers need to evaluate anticancer activity, compare candidate therapies, or choose experimental conditions for follow-up work. By linking defined exposure conditions with viability-associated signals, the assay provides quantitative evidence for treatment effects. Its results can support studies of cancer biology and contribute to early preclinical development decisions.